Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus

Amgen (NASDAQ: AMGN) reported Q3 EPS of $4.67, $0.41 better than the analyst estimate of $4.26. Revenue for the quarter came in at $6.71 billion versus the consensus estimate of $6.69 billion.

GUIDANCE:

Amgen sees FY2021 EPS of $16.50-$17.10, versus the consensus of $16.43. Amgen sees FY2021 revenue of $25.8-26.2 billion, versus the consensus of $26 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• FTC files amicus brief challenging Amgen's Enbrel patent acquisition
• Is the global equity rally broadening? UBS weighs in
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance